Matching articles for "January 25"
Issue 1333 · March 8, 2010 Free
Addendum: Cost of Ustekinumab (Stelara)

In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.

Med Lett Drugs Ther. 2010 Mar 8; 52(1333):20
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7) , footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
Issue 1330 · January 25, 2010
Medical Marijuana

Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):5-6
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa) . In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use.
Issue 1330 · January 25, 2010 Free
Glucose Control in the ICU

Once thought to be a beneficial response to critical illness, hyperglycemia is now recognized as independently associated with death and other adverse outcomes in various groups of critically ill patients.…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):6-7
Once thought to be a beneficial response to critical illness, hyperglycemia is now recognized as independently associated with death and other adverse outcomes in various groups of critically ill patients. Whether normalization of blood glucose by insulin infusion is beneficial in such patients has been a subject of debate in the critical care community. Some new guidelines have been published. Click here to view the free full article.
Issue 1330 · January 25, 2010
Ustekinumab (Stelara) for Psoriasis

The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis.…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):7-8
The FDA has approved the use of ustekinumab ( Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors.